A Trial of SHR3680 in Prostate Cancer Patients Who Are Candidates for Radical Prostatectomy
Status:
Not yet recruiting
Trial end date:
2031-10-30
Target enrollment:
Participant gender:
Summary
The study is being conducted to evaluate the efficacy and safety of SHR3680 plus androgen
deprivation therapy (ADT) vs. placebo plus ADT in patients with high-risk localized or
locally advanced prostate cancer using pathologic complete response (pCR) rate and
metastasis-free survival (MFS).